Call our 24 hours, seven days a week helpline at 800.272.3900

24/7 Helpline 800.272.3900
Donate

Alzheimer's Association Statement on FDA Decision to Hold Advisory Committee Meeting to Discuss Donanemab

Alzheimer's Association Statement on FDA Decision to Hold Advisory Committee Meeting to Discuss Donanemab
Share or Print this page
Share or Print this page
March 8, 2024
Email: media@alz.org
Share or Print this page

CHICAGO, March 8, 2024 — The Alzheimer's Association appreciates the Food and Drug Administration's (FDA) thorough process in reviewing treatments for Alzheimer's disease. The FDA has determined it will hold an advisory committee meeting on donanemab (Lilly). While the decision is a surprise at this stage in the review process, the safety and appropriate administration of treatments is paramount.

On behalf of everyone who could benefit from this treatment, we strongly urge the FDA to move swiftly in this next stage of its review.

About the Alzheimer's Association

The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.

Keep Up With Alzheimer’s News and Events